Trials / Completed
CompletedNCT01164007
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
Phase II Study of Dacarbazine With the Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Patients With Unresectable/Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the preliminary anti-tumor activity and safety profile of a combination of bevacizumab and dacarbazine in participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle. |
| DRUG | Dacarbazine | Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle. |
Timeline
- Start date
- 2006-06-30
- Primary completion
- 2012-05-31
- Completion
- 2012-05-31
- First posted
- 2010-07-16
- Last updated
- 2017-04-21
- Results posted
- 2017-04-21
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01164007. Inclusion in this directory is not an endorsement.